Ascendis Pharma A/SASNDNASDAQ
Loading
R&D Expenses Over TimeStable
Percentile Rank69
3Y CAGR-9.3%
5Y CAGR+1.7%
Studio
Year-over-Year Change

Research and development spending

3Y CAGR
-9.3%/yr
vs +28.3%/yr prior
5Y CAGR
+1.7%/yr
Recent deceleration
Acceleration
-37.5pp
Decelerating
Percentile
P69
Within normal range
vs 5Y Ago
1.1x
Modest growth
Streak
2 yr
Consecutive declineStable
PeriodValueYoY Change
2025$283.50M-7.7%
2024$307.00M-25.7%
2023$413.45M+8.9%
2022$379.62M+28.3%
2021$295.87M+13.4%
2020$260.90M+36.2%
2019$191.62M+36.6%
2018$140.28M+40.9%
2017$99.59M+50.8%
2016$66.02M-